TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cannara Biotech ( (TSE:LOVE) ) has provided an update.
Cannara Biotech Inc. announced it will release its fiscal Q4 and full-year 2025 financial results on November 24, 2025. The announcement will be accompanied by an earnings webcast hosted by CEO Zohar Krivorot and CFO Nicholas Sosiak. Additionally, the company mourns the loss of Jack M. Kay, a valued board member with extensive leadership experience in the pharmaceutical and biotechnology sectors. His passing is a significant loss to the company and the broader industry.
The most recent analyst rating on (TSE:LOVE) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Cannara Biotech stock, see the TSE:LOVE Stock Forecast page.
Spark’s Take on TSE:LOVE Stock
According to Spark, TipRanks’ AI Analyst, TSE:LOVE is a Outperform.
Cannara Biotech’s strong financial performance, characterized by impressive revenue growth and profitability, is the most significant factor driving the stock score. The technical analysis suggests a neutral trend with potential for upward movement, while the valuation indicates a reasonable price relative to earnings. The absence of earnings call data and corporate events does not impact the score.
To see Spark’s full report on TSE:LOVE stock, click here.
More about Cannara Biotech
Cannara Biotech Inc. is a vertically integrated producer of premium-grade cannabis products, focusing on the Canadian market. The company operates two mega facilities in Québec, offering a potential annualized cultivation output of 100,000 kg, and benefits from low electricity costs to produce affordable cannabis products.
YTD Price Performance: 102.50%
Average Trading Volume: 45,849
Technical Sentiment Signal: Buy
Current Market Cap: C$148.1M
See more data about LOVE stock on TipRanks’ Stock Analysis page.